SBTX vs. NLTX, AVIR, ORGO, FBLG, RANI, ERAS, URGN, TERN, KMDA, and PGEN
Should you be buying Silverback Therapeutics stock or one of its competitors? The main competitors of Silverback Therapeutics include Neoleukin Therapeutics (NLTX), Atea Pharmaceuticals (AVIR), Organogenesis (ORGO), FibroBiologics (FBLG), Rani Therapeutics (RANI), Erasca (ERAS), UroGen Pharma (URGN), Terns Pharmaceuticals (TERN), Kamada (KMDA), and Precigen (PGEN). These companies are all part of the "pharmaceutical preparations" industry.
Silverback Therapeutics (NASDAQ:SBTX) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, community ranking, earnings, profitability and institutional ownership.
In the previous week, Silverback Therapeutics' average media sentiment score of 0.00 equaled Neoleukin Therapeutics'average media sentiment score.
Silverback Therapeutics' return on equity of -29.62% beat Neoleukin Therapeutics' return on equity.
Silverback Therapeutics has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500.
74.9% of Silverback Therapeutics shares are owned by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.
Neoleukin Therapeutics received 32 more outperform votes than Silverback Therapeutics when rated by MarketBeat users. However, 56.25% of users gave Silverback Therapeutics an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote.
Neoleukin Therapeutics has a consensus target price of $30.00, indicating a potential downside of 11.61%. Given Neoleukin Therapeutics' higher possible upside, analysts plainly believe Neoleukin Therapeutics is more favorable than Silverback Therapeutics.
Summary
Silverback Therapeutics beats Neoleukin Therapeutics on 7 of the 11 factors compared between the two stocks.
Get Silverback Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Silverback Therapeutics Competitors List
Related Companies and Tools
